[Proliferative markers of meningiomas: immunohistochemical analysis and prognostic value].
Routine pathological examination cannot precisely predict the clinical course of meningiomas because even histologically benign tumors may recur after total removal. And so, numerous efforts have been made for evaluation of meningioma growth fraction and its prognostic value. In this study the prognostic significance of DNA toposiomerase II alpha (topoII) and cyclin A immunohistochemistry was examined in a series of 263 meningiomas. The topoII and cyclin A scores exhibited a close correlation with Ki-67 immunostaining. Significant differences between the indices for all the three markers were noted among the three grades of meningiomas. The scores for all the three markers were significantly different between recurrent and non-recurrent meningiomas including removed benign tumors. The most important information for an individual clinical outcome of histologically benign meningiomas should be elicited from simultaneous evaluation of all the three proliferative markers.
Korshunov
A G
AG
N.N. Burdenko Research Institute of Neurosurgery, 125047, Moscow.
Shishkina
L V
LV
Golanov
A V
AV
D000328:Adult; D014408:Biomarkers, Tumor / Q000096:biosynthesis; D019925:Cyclin A / Q000096:biosynthesis; D004250:DNA Topoisomerases, Type II / Q000096:biosynthesis; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000096:biosynthesis; D008297:Male; D008577:Meningeal Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology*; D008579:Meningioma / Q000378:metabolism* / Q000401:mortality / Q000473:pathology*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000378:metabolism* / Q000401:mortality / Q000473:pathology*; D011237:Predictive Value of Tests
D014408:Biomarkers, Tumor; D019925:Cyclin A; D019394:Ki-67 Antigen; D004250:DNA Topoisomerases, Type II